Compare BYND & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYND | XFOR |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.2M | 276.3M |
| IPO Year | 2018 | N/A |
| Metric | BYND | XFOR |
|---|---|---|
| Price | $0.79 | $3.73 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $1.70 | ★ $28.50 |
| AVG Volume (30 Days) | ★ 30.2M | 543.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.80 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $326,452,000.00 | N/A |
| Revenue This Year | N/A | $1,263.94 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.17 |
| 52 Week High | $7.69 | $6.63 |
| Indicator | BYND | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 56.63 |
| Support Level | $0.67 | $3.52 |
| Resistance Level | $0.82 | $4.09 |
| Average True Range (ATR) | 0.08 | 0.23 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 28.25 | 83.50 |
Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.